Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alfredo Addeo

Showing results (181-190 of 224) with videos related to

Pageof 23
Sort By:
Frontiers in Oncology|June 16, 2023
Immunotherapy-related adverse events in real-world patients with advanced non-small cell lung cancer on chemoimmunotherapy: a Spinnaker study sub-analysisShobana Anpalakhan, Prerana Huddar, Roya Behrouzi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2003
PCR-detectable nonneoplastic Bcl-2/IgH rearrangements are common in normal subjects and cancer patients at diagnosis but rare in subjects treated with chemotherapyMarco Ladetto, Daniela Drandi, Mara Compagno, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|January 28, 2026
Real-world outcomes of stage III NSCLCs managed by surgery or definitive radiation therapy in the era of immunotherapyEtienne Abdelnour-Berchtold, Louis-Emmanuel Chriqui, Laetitia Zermatten, et al.
European Journal of Cancer (Oxford, England : 1990)|September 18, 2021
Patient-reported outcomes for monitoring symptomatic toxicities in cancer patients treated with immune-checkpoint inhibitors: A Delphi studyAndré Manuel Da Silva Lopes, Sara Colomer-Lahiguera, Nuria Mederos Alfonso, et al.
Revue Medicale Suisse|December 11, 2025
[Involving Patient Partners: Platforms and Strategies in French-Speaking Switzerland]Hélène Chanvrier, Alfredo Addeo, Cindy Allenbach, et al.
Vaccines|August 26, 2023
SARS-CoV-2 m-RNA Vaccine Response in Immunocompromised Patients: A Monocentric Study Comparing Cancer, People Living with HIV, Hematopoietic Stem Cell Transplant Patients and Lung Transplant RecipientsNatacha Bordry, Anne-Claire Mamez, Chiara Fedeli, et al.
Lung Cancer (Amsterdam, Netherlands)|June 6, 2022
A prognostic score for patients with malignant pleural mesothelioma (MPM) receiving second-line immunotherapy or chemotherapy in the ETOP 9-15 PROMISE-meso phase III trialGiuseppe Luigi Banna, Alfredo Addeo, Panagiota Zygoura, et al.
Iscience|January 3, 2022
Humoral and cellular immunogenicity two months after SARS-CoV-2 messenger RNA vaccines in patients with cancerNatacha Bordry, Alfredo Addeo, Cyril Jaksic, et al.
Acta Oncologica (Stockholm, Sweden)|August 9, 2020
Impact of performance status on non-small-cell lung cancer patients with a PD-L1 tumour proportion score ≥50% treated with front-line pembrolizumabAlex Friedlaender, Giulio Metro, Diego Signorelli, et al.
Journal of Thoracic Disease|February 8, 2020
Outcomes from salvage chemotherapy or pembrolizumab beyond progression with or without local ablative therapies for advanced non-small cell lung cancers with PD-L1 ≥50% who progress on first-line immunotherapy: real-world data from a European cohortGiulio Metro, Alfredo Addeo, Diego Signorelli, et al.
Pageof 23

Showing results (181-190 of 224) with videos related to

Sort By:
Pageof 23
Frontiers in Oncology|June 16, 2023
Immunotherapy-related adverse events in real-world patients with advanced non-small cell lung cancer on chemoimmunotherapy: a Spinnaker study sub-analysisShobana Anpalakhan, Prerana Huddar, Roya Behrouzi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2003
PCR-detectable nonneoplastic Bcl-2/IgH rearrangements are common in normal subjects and cancer patients at diagnosis but rare in subjects treated with chemotherapyMarco Ladetto, Daniela Drandi, Mara Compagno, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|January 28, 2026
Real-world outcomes of stage III NSCLCs managed by surgery or definitive radiation therapy in the era of immunotherapyEtienne Abdelnour-Berchtold, Louis-Emmanuel Chriqui, Laetitia Zermatten, et al.
European Journal of Cancer (Oxford, England : 1990)|September 18, 2021
Patient-reported outcomes for monitoring symptomatic toxicities in cancer patients treated with immune-checkpoint inhibitors: A Delphi studyAndré Manuel Da Silva Lopes, Sara Colomer-Lahiguera, Nuria Mederos Alfonso, et al.
Revue Medicale Suisse|December 11, 2025
[Involving Patient Partners: Platforms and Strategies in French-Speaking Switzerland]Hélène Chanvrier, Alfredo Addeo, Cindy Allenbach, et al.
Vaccines|August 26, 2023
SARS-CoV-2 m-RNA Vaccine Response in Immunocompromised Patients: A Monocentric Study Comparing Cancer, People Living with HIV, Hematopoietic Stem Cell Transplant Patients and Lung Transplant RecipientsNatacha Bordry, Anne-Claire Mamez, Chiara Fedeli, et al.
Lung Cancer (Amsterdam, Netherlands)|June 6, 2022
A prognostic score for patients with malignant pleural mesothelioma (MPM) receiving second-line immunotherapy or chemotherapy in the ETOP 9-15 PROMISE-meso phase III trialGiuseppe Luigi Banna, Alfredo Addeo, Panagiota Zygoura, et al.
Iscience|January 3, 2022
Humoral and cellular immunogenicity two months after SARS-CoV-2 messenger RNA vaccines in patients with cancerNatacha Bordry, Alfredo Addeo, Cyril Jaksic, et al.
Acta Oncologica (Stockholm, Sweden)|August 9, 2020
Impact of performance status on non-small-cell lung cancer patients with a PD-L1 tumour proportion score ≥50% treated with front-line pembrolizumabAlex Friedlaender, Giulio Metro, Diego Signorelli, et al.
Journal of Thoracic Disease|February 8, 2020
Outcomes from salvage chemotherapy or pembrolizumab beyond progression with or without local ablative therapies for advanced non-small cell lung cancers with PD-L1 ≥50% who progress on first-line immunotherapy: real-world data from a European cohortGiulio Metro, Alfredo Addeo, Diego Signorelli, et al.
Pageof 23